A5075761575- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases
- Medical Imaging and Pathology Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Nanoplatforms for cancer theranostics
- Lung Cancer Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Photodynamic Therapy Research Studies
- Gut microbiota and health
- Vascular Tumors and Angiosarcomas
- Lung Cancer Treatments and Mutations
- Childhood Cancer Survivors' Quality of Life
- Cellular Mechanics and Interactions
University of Lausanne
2021-2025
Swiss Cancer Center Léman
2024
University Hospital of Lausanne
2024
<div>Abstract<p>Pleural mesothelioma is a fatal disease with limited treatment options. Recently, pleural management has improved the development of immune checkpoint inhibitors (ICI). In first-line therapy, dual PD-1 and CTLA-4 blockade enhances tumor control patient survival compared chemotherapy. Unfortunately, only fraction patients responsive to immunotherapy, approaches reshape microenvironment make ICIs more effective are urgently required. this study, we evaluated effect...
<p>Supplementary Figure S5: Impact of HITOC on tumor-infiltrating T cells.</p>
<p>Supplementary Figure S3: Representative flow cytometry histograms.</p>
<p>Supplementary Figure S4: Effect of HITOC on CD4 T cell infiltration in tumors.</p>
<p>Supplementary Figure S1: Evaluation of the impact heat adjunct on cisplatin cytotoxicity.</p>
<p>Supplementary Figure S6: Effect of HITOC on PD-1 and CTLA-4 expression by CD4 T cells.</p>
<p>Supplementary Figure S2: Flow cytometry gating.</p>
Abstract Background Advances in non-small cell lung cancer (NSCLC) management have extended survival rates, contributing to a higher incidence of second primary NSCLC (2-20%). Repeated anatomical pulmonary resection these cases poses significant technical challenges and functional limitations due previous surgery. Aims This study evaluates the feasibility short-term outcomes repeated resections for NSCLC. Methods We retrospectively reviewed all consecutive performed our institution from...
Abstract Background Neoadjuvant chemo-immunotherapy has become a standard for management of resectable stage III non-small cell lung cancer (NSCLC) patients with improved overall survival. Post-induction radiological re-staging, commonly performed CT scan, is crucial in surgical planning. Aims This study evaluates the predictive value PET-CT scan after neo-adjuvant to predict tumor response and patient Methods We analyzed, our prospectively collected database, 68 resectables N2 NSCLC treated...
Abstract Pleural mesothelioma is a fatal disease with limited treatment options. Recently, pleural management has improved the development of immune checkpoint inhibitors (ICI). In first-line therapy, dual PD-1 and CTLA-4 blockade enhances tumor control patient survival compared chemotherapy. Unfortunately, only fraction patients responsive to immunotherapy, approaches reshape microenvironment make ICIs more effective are urgently required. this study, we evaluated effect hyperthermic...
Pleural carcinosis originates from various cancers. Its management consists in systemic palliative therapies combined to dyspnea relief procedures. Prior studies have shown limited activity of normo/hypethermic intrathoracic chemotherapy treat pleural carcinosis. These approaches could not be generalized because restricted cytostatic penetration tumors and local toxicity. Preclinical data demonstrate that hyperthermia induces an immunogenic response directed against cancer further enhanced...
Abstract Background Resectable locally advanced non-small cell lung cancers (NSCLCs) are managed by multimodal approaches including systemic therapies followed surgery. The recent inclusion of immunotherapy in neoadjuvant protocols has significantly improved tumor responses. In selected situations, bulky N2, N3 or oligometastatic NSCLCs with treated metastasis have shown excellent regression following chemo-immunotherapy and could be considered for Aims We here compare the oncological...
Abstract Background The management of malignant pleural mesothelioma (MPM) remains challenging with poor patient survival. Local therapies such as hyperthermic intrathoracic cisplatin (HITOC) have shown good tumor control in selected patients. HITOC was to increase MPM drug exposure while limiting systemic side effects but alternative mechanisms for are still lacking. Aims We hypothesized that induces an immune response directed against which decreases cancer related mortality. Methods A...
Abstract Objective Malignant pleural mesothelioma (MPM) is a deadly disease with limited treatment options. Recently, dual immune checkpoint inhibition therapy (ICI) showed improved patient survival. However, only fraction of patients were responsive to immunotherapy. One potential mechanism MPM resistance ICIs could be their endothelial anergy that hampers leukocyte trafficking the tumor bulk. Here, we hypothesized vascular-targeted low dose photodynamic (L-PDT), relieve and improve...
Abstract Objective Immune checkpoint inhibition (ICI) therapy has revolutionized the outcome of certain cancers such as malignant pleural mesothelioma (MPM). However, patient responsiveness to this treatment remains unpredictable. Recently, a role for gut microbiota composition emerged patients generate robust immune response against their tumors, following immunotherapy. Here, we studied impact Prembion®, pre-biotic and modulator microbiota, on tumor control lymphocyte infiltration in...
Abstract Objective Malignant pleural mesothelioma (MPM) is a deadly disease with dismal prognosis. Prior studies combining surgery intrapleural hyperthermic chemotherapy (IPHC) have shown improved survivals in selected patients MPM. However, the mechanisms by which IPHC acts on MPM and its microenvironment remains unknown. Here we focus tumor endothelial adhesion molecule expression patterns. Methods First, determined impact of vascular compartments vitro using novel bioincubater for cell...